Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

Embecta Corp.

EMBCNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On August 7, 2026, Embecta Corp. issued a press release (the “Press Release”) regarding its results for the quarter ended June 30, 2026. The Press Release is furnished as Exhibit 99.1 to this report.

Filed Aug 7, 2026Accepted Aug 7, 2026, 7:07 AM EDTCIK 1872789Accession 0001872789-26-000029
Share

Company context

embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

Current securities

Historical securities (1)

Recent company filings

  1. 4 filingSep 8, 2026
  2. 4 filingAug 13, 2026
  3. 4 filingAug 13, 2026
  4. S-8 filingAug 7, 2026
  5. 10-Q filingAug 7, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition. On August 7, 2026, Embecta Corp. issued a press release (the “Press Release”) regarding its results for the quarter ended June 30, 2026. The Press Release is furnished as Exhibit 99.1 to this report.
Filed exhibits (1)
EX-99.1 (by filename) q32026ex-991.htm

EX-99.1 2 q32026ex-991.htm EX-99.1 Document FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Aug 7, 2026 (GLOBE NEWSWIRE) - Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2026. "Our third quarter results improved significantly on a sequential basis, with revenue increasing approximately $50 million, GAAP operating income increasing approximately $14 million, and adjusted operating income increasing approximately $21 million as compared to our second quarter results. The sequential increase was due to a combination of factors, including improved performance within the United States and International, as well as contribution from the acquisition of Owen Mumford which closed mid-way through our third quarter," said Devdatt (Dev) Kurdikar, Chairman, President and Chief Executive Officer of embecta. Mr. Kurdikar continued, "We repaid approximately $53 million of debt during the quarter and also repurchased approximately $9 million of shares under our three-year, up to $100 million share repurcha…

Open exhibit ↗